atrasentan has been researched along with piperidines in 12 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 40,235 | 5,221 | 14,545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| D'Orléans-Juste, P; Piovezan, AP; Rae, GA; Souza, GE | 1 |
| Chen, YF; Oparil, S | 1 |
| Curtis, TM; Scholfield, CN | 1 |
| Fujimori, A; Fujiyasu, N; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H | 1 |
| Fujimori, A; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H | 1 |
| Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR | 1 |
| Gariepy, CE; Tykocki, NR; Watts, SW | 1 |
| Boemke, W; Francis, RC; Höhne, C; Kaisers, UX; Klein, A; Pickerodt, PA | 1 |
| Boesen, EI; Pollock, DM; Pollock, JS; Saleh, MA; Savin, VJ | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| El-Din, MM; El-Mas, MM; Elmallah, AI; Khedr, MM; Nasser, SA; Sabra, R | 1 |
| Bądzyńska, B; Hojná, S; Kompanowska-Jezierska, E; Sadowski, J; Vaneckova, I | 1 |
1 review(s) available for atrasentan and piperidines
| Article | Year |
|---|---|
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
11 other study(ies) available for atrasentan and piperidines
| Article | Year |
|---|---|
Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation.
Topics: Animals; Atrasentan; Capsaicin; Edema; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hyperalgesia; Male; Mice; Nociceptors; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Viper Venoms | 2000 |
Evidence for two endothelin Et(A) receptor subtypes in rabbit arteriolar smooth muscle.
Topics: Animals; Arterioles; Atrasentan; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Choroid; Culture Techniques; Endothelin Receptor Antagonists; Endothelin-1; Female; Ion Transport; Male; Membrane Potentials; Muscle, Smooth, Vascular; Oligopeptides; Patch-Clamp Techniques; Peptides, Cyclic; Piperidines; Pyrrolidines; Rabbits; Receptor, Endothelin A; Receptors, Endothelin | 2001 |
Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
Topics: Atrasentan; Binding, Competitive; Blood Pressure; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Iodine Radioisotopes; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrrolidines; Radioligand Assay; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Viper Venoms | 2004 |
Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Topics: Administration, Oral; Animals; Atrasentan; Binding, Competitive; Biological Availability; Blood Pressure; Bosentan; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Injections, Intravenous; Muscle, Smooth, Vascular; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Viper Venoms | 2004 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold Temperature; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin-1; Endothelins; Grooming; Hyperalgesia; Indomethacin; Male; Maxillary Nerve; Nerve Compression Syndromes; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Trigeminal Neuralgia | 2006 |
Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Atrasentan; Dinoprost; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelium, Vascular; In Vitro Techniques; Male; Nitroarginine; Oligopeptides; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Tunica Intima; Tunica Media; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Venae Cavae; Viper Venoms | 2009 |
Endothelin receptor subtype A blockade does not affect the haemodynamic recovery from haemorrhage during xenon/remifentanil or isoflurane/remifentanil anaesthesia in dogs.
Topics: Anesthesia; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Atrasentan; Blood Loss, Surgical; Catecholamines; Dog Diseases; Dogs; Endothelin A Receptor Antagonists; Endothelin-1; Epinephrine; Female; Hemodynamics; Hemorrhage; Isoflurane; Norepinephrine; Piperidines; Pyrrolidines; Remifentanil; Time Factors; Vascular Resistance; Vasopressins; Xenon | 2010 |
Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.
Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelin A Receptor Antagonists; Immunoassay; Kidney Glomerulus; Male; Membrane Proteins; Oligopeptides; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 2011 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Aorta; Atrasentan; Baroreflex; Blood Pressure; Captopril; Cyclosporine; Hypertension; Indomethacin; Losartan; Male; Naphthalenes; Nitric Oxide Synthase Type III; Nitroprusside; Oligopeptides; Phenylephrine; Piperidines; Propionates; Pyrrolidines; Rats; Renin-Angiotensin System; Vasoconstriction; Vasodilation | 2016 |
Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension; Kidney; Nitric Oxide; Oligopeptides; Piperidines; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Endothelin A; Renal Elimination | 2021 |